RE:RE:RE:Pancreatic cancer data a game changer for this stockIn my opinion, the tone of this Webinar seemed very differtent than anything in the past.
In a very positive way.
Not just the news, but the way things were presented and discussed.
Not once did they state pela is well tonerated, etc...blah, blah blah...
It seems we have moved beyond that now.
This webinar had some real meat to it.
We are now looking at the end stokes, quickly approaching registration.
Included more comments on the management side of things and expainations for such actions or percieved non-actions. Nice and thanks!
Actual end points with 'a major media event' presentation in Q4... Put that date in your calendar, once we have a date.... exciting.
It felt like a real 'State of the Union' address, with real projections and expectations, that I belive, Shareholders can get behind now... even the shorters I think will get behind this. I think the shorting days are over for ONC based on this Webinar.
It is my expectation that we will see a steady climb until the 'major media event', but remember, nothing goes straight up forever, there will be downward spikes for profit taking along the way, but an over all climb do I expect until the 'major media event'.
Along with that, I fully expect that once the ONCY USA SP is over $5, we will see an influx of instituitioanl buyers jumping in and volume will spike and we just might see that $12 to$15 target price by Oct/Nov.
As much as the webinar all talks up the partnership agreements, etc, I still favour Roche to just buy ONC out before Oct/Nov. Before Pfizer can come to any final conclusions. Only time will tell.
TWO PHASE III registration trails potentially just around the corner.
One trial solely with Roche.
CAR T in the back pocket
I noted that they did not discuss the Biospecific stuff that Roche has been moving into.. likely due to the cone of silience.. I'll wait...
Nice !
Good luck everyone!
Have great weekend!